-
Decision (SBD) for
Tecartus".
Health Canada. 23
October 2014.
Archived from the
original on 29 May 2022.
Retrieved 29 May 2022. "
Tecartus- brexucabtagene...
-
medical use in the
United States in
January 2023.
Brexucabtagene autoleucel (
Tecartus) was
approved for
medical use in the
United States in July 2020, with an...
-
effect on
anxiety and
serious adverse events.
Brexucabtagene autoleucel (
Tecartus) was
approved by the FDA in
October 2021 for the
treatment of
adults with...
- and
Research (2021-03-04). "
TECARTUS (brexucabtagene autoleucel)". FDA.
European Medicines Agency (2023-01-30). "
TECARTUS (brexucabtagene autoleucel)"...
-
Archived from the
original on 2
October 2021.
Retrieved 2
October 2021. "
Tecartus".
European Medicines Agency. 13
October 2020. "FDA
Approves First Gene...
- (INN)
tebuquine (INN)
tecadenoson (USAN)
tecalcet (USAN)
tecarfarin (USAN)
Tecartus tecastemizole (USAN)
teceleukin (INN)
Tecelra Tecentriq Tecentriq Hybreza...
-
acquisition had led to two
marketed products for lymphoma:
Yescarta and
Tecartus. In November, the
company announced it will
acquire Cell
Design Labs for...
- (Zynteglo):
treatment for beta thal****emia
Brexucabtagene autoleucel (
Tecartus):
treatment for
mantle cell
lymphoma and
acute lymphoblastic leukemia Cambiogenplasmid...
- and
pediatric B-Cell
precursor acute lymphoblastic leukemia: Yescarta,
Tecartus (brexucabtagene autoleucel),
Breyanzi (lisocabtagene maraleucel), Carvykti...
- Allocord, Clevecord, and Omisirge); CART
products (Kymriah, Yescarta,
Tecartus, Breyanzi, Abecma, and Carvykti); gene
therapies Zynteglo, Casgevy, Skysona...
